Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Pfenex Inc's Business Segments
Pfenex Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Pfenex Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- License and Service94.9%
- Product5.1%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Service | $ 1 | 94.9% |
| Product | $ 0 | 5.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Pfenex Inc
Pfenex Inc is a biotechnology company that specializes in the development of innovative protein-based therapeutics and vaccines. The company was founded in 2009 by a team of experienced scientists and executives dedicated to advancing the science of protein engineering and expression.
The company's technology platform is based on a proprietary protein expression system that allows for the rapid and cost-effective production of recombinant proteins. This system enables the company to overcome many of the limitations of traditional protein expression systems, including low yields, slow production times, and difficulty in expressing certain types of proteins.
Pfenex Inc's technology is particularly well-suited to the development of complex protein therapeutics, such as those used to treat cancer, autoimmune disorders, and infectious diseases. The company is currently developing a number of novel protein-based therapeutics that have the potential to transform the way these diseases are treated.
One of the key advantages of Pfenex Inc's technology is its ability to produce high-quality proteins that are free of impurities and contaminants. This is due to the company's extensive expertise in protein engineering, purification, and characterization.
In addition to its work on protein therapeutics, Pfenex Inc is also developing a number of vaccine candidates, including a novel vaccine for COVID-19. The company's vaccine technology is based on its proprietary expression system, which allows for the rapid production of large quantities of vaccine antigens.
Pfenex Inc has a strong track record of successful collaborations with leading pharmaceutical and biotechnology companies. The company has partnered with a number of companies to develop protein-based therapeutics and vaccines for a range of diseases.
Overall, Pfenex Inc is a leading player in the field of protein engineering and expression. The company's proprietary technology platform, deep expertise in protein engineering and purification, and strong partnerships make it well-positioned to continue to develop innovative protein-based therapeutics and vaccines that have the potential to transform the lives of patients around the world.
The company's technology platform is based on a proprietary protein expression system that allows for the rapid and cost-effective production of recombinant proteins. This system enables the company to overcome many of the limitations of traditional protein expression systems, including low yields, slow production times, and difficulty in expressing certain types of proteins.
Pfenex Inc's technology is particularly well-suited to the development of complex protein therapeutics, such as those used to treat cancer, autoimmune disorders, and infectious diseases. The company is currently developing a number of novel protein-based therapeutics that have the potential to transform the way these diseases are treated.
One of the key advantages of Pfenex Inc's technology is its ability to produce high-quality proteins that are free of impurities and contaminants. This is due to the company's extensive expertise in protein engineering, purification, and characterization.
In addition to its work on protein therapeutics, Pfenex Inc is also developing a number of vaccine candidates, including a novel vaccine for COVID-19. The company's vaccine technology is based on its proprietary expression system, which allows for the rapid production of large quantities of vaccine antigens.
Pfenex Inc has a strong track record of successful collaborations with leading pharmaceutical and biotechnology companies. The company has partnered with a number of companies to develop protein-based therapeutics and vaccines for a range of diseases.
Overall, Pfenex Inc is a leading player in the field of protein engineering and expression. The company's proprietary technology platform, deep expertise in protein engineering and purification, and strong partnerships make it well-positioned to continue to develop innovative protein-based therapeutics and vaccines that have the potential to transform the lives of patients around the world.
Pfenex Inc is an innovative biotechnology company that emphasizes the development and production of protein-based products and services specifically tailored for the healthcare industry. The organization operates within two primary segments—research and development (R&D) and commercialization—allowing it to address both the creation of new therapies and their functional deployment in the market.
Segments:
1. Research and Development (R&D):
In this segment, Pfenex Inc focuses on conducting comprehensive research aimed at discovering and developing new protein therapeutics and vaccines. The R&D efforts involve extensive experimentation and the application of cutting-edge biotechnological methods, aiming to pioneer innovative treatments for diseases with limited or ineffective therapies. This segment is crucial for addressing medical gaps and expanding the pharmacological arsenal against various diseases, particularly rare and challenging conditions.
2. Commercialization:
This segment encompasses the production of commercially viable products intended for the pharmaceutical market. Pfenex Inc effectively translates its R&D breakthroughs into market-ready therapeutics and vaccines. The commercialization strategy includes the establishment of partnerships and collaborations with pharmaceutical companies to facilitate distribution and access to these advanced protein-based drugs.
Products:
Pfenex Inc boasts a diverse portfolio of products, each developed to meet specific healthcare needs. Key products include:
1. PF743:
Designed specifically for the treatment of phenylketonuria (PKU), PF743 is a recombinant protein that targets metabolic disorders. PKU is a genetic condition that can lead to serious neurodevelopmental issues if left untreated, making this product vital for patients who have limited alternatives for management.
2. PF708:
PF708 is a biosimilar to Teriparatide, focusing on the treatment and prevention of osteoporosis and related bone fractures. The biosimilar approach enables a more accessible and cost-effective option for patients requiring therapeutic interventions to improve bone health.
3. Recombinant Influenza Vaccine:
This product represents an advancement in vaccine technology, providing a recombinant version of the influenza vaccine. It offers advantages over traditional egg-based vaccines, including increased safety and efficiency, as well as a potentially quicker turnaround during flu season or pandemics.
4. Px563L:
Currently in phase 2 clinical trials, Px563L is a recombinant protein derived from propionibacterium, aimed at addressing vitamin B12 deficiency. This product has the potential to provide a novel therapeutic option for individuals suffering from this deficiency, which can lead to significant health complications.
Services:
Pfenex Inc also provides a suite of services designed to support biopharmaceutical development and manufacturing processes:
1. Protein Expression Technology:
The company specializes in advanced protein expression technologies that facilitate the production of functional proteins critical for research and therapeutic applications.
2. Protein Production Services:
Pfenex Inc offers comprehensive protein production services tailored for the biotherapeutic proteins necessary for preclinical and clinical trial phases. These services are essential for advancing potential new drugs through various stages of development.
3. Gene to GMP Services:
The Gene to GMP (Good Manufacturing Practice) service encompasses the complete journey from gene sequence development to the compliant production of proteins intended for clinical and commercial use. This service ensures high-quality, regulatory-approved products.
4. Protein Engineering Services:
To enhance the characteristics of proteins for biologic applications, Pfenex Inc provides protein engineering services. These services focus on optimizing biophysical properties, improving usability, efficacy, and stability of therapeutic proteins.
Conclusion:
Pfenex Inc stands out as a biotechnology leader with a robust range of products and services designed to meet diverse healthcare needs. With a strong commitment to advancing research and development, the company is poised to deliver groundbreaking protein therapies and vaccines, addressing significant challenges in patient care and contributing positively to the healthcare landscape. Through its focus on innovation and collaboration, Pfenex Inc continues to enhance its capabilities to tackle chronic and complex diseases, ultimately improving patient outcomes.
Segments:
1. Research and Development (R&D):
In this segment, Pfenex Inc focuses on conducting comprehensive research aimed at discovering and developing new protein therapeutics and vaccines. The R&D efforts involve extensive experimentation and the application of cutting-edge biotechnological methods, aiming to pioneer innovative treatments for diseases with limited or ineffective therapies. This segment is crucial for addressing medical gaps and expanding the pharmacological arsenal against various diseases, particularly rare and challenging conditions.
2. Commercialization:
This segment encompasses the production of commercially viable products intended for the pharmaceutical market. Pfenex Inc effectively translates its R&D breakthroughs into market-ready therapeutics and vaccines. The commercialization strategy includes the establishment of partnerships and collaborations with pharmaceutical companies to facilitate distribution and access to these advanced protein-based drugs.
Products:
Pfenex Inc boasts a diverse portfolio of products, each developed to meet specific healthcare needs. Key products include:
1. PF743:
Designed specifically for the treatment of phenylketonuria (PKU), PF743 is a recombinant protein that targets metabolic disorders. PKU is a genetic condition that can lead to serious neurodevelopmental issues if left untreated, making this product vital for patients who have limited alternatives for management.
2. PF708:
PF708 is a biosimilar to Teriparatide, focusing on the treatment and prevention of osteoporosis and related bone fractures. The biosimilar approach enables a more accessible and cost-effective option for patients requiring therapeutic interventions to improve bone health.
3. Recombinant Influenza Vaccine:
This product represents an advancement in vaccine technology, providing a recombinant version of the influenza vaccine. It offers advantages over traditional egg-based vaccines, including increased safety and efficiency, as well as a potentially quicker turnaround during flu season or pandemics.
4. Px563L:
Currently in phase 2 clinical trials, Px563L is a recombinant protein derived from propionibacterium, aimed at addressing vitamin B12 deficiency. This product has the potential to provide a novel therapeutic option for individuals suffering from this deficiency, which can lead to significant health complications.
Services:
Pfenex Inc also provides a suite of services designed to support biopharmaceutical development and manufacturing processes:
1. Protein Expression Technology:
The company specializes in advanced protein expression technologies that facilitate the production of functional proteins critical for research and therapeutic applications.
2. Protein Production Services:
Pfenex Inc offers comprehensive protein production services tailored for the biotherapeutic proteins necessary for preclinical and clinical trial phases. These services are essential for advancing potential new drugs through various stages of development.
3. Gene to GMP Services:
The Gene to GMP (Good Manufacturing Practice) service encompasses the complete journey from gene sequence development to the compliant production of proteins intended for clinical and commercial use. This service ensures high-quality, regulatory-approved products.
4. Protein Engineering Services:
To enhance the characteristics of proteins for biologic applications, Pfenex Inc provides protein engineering services. These services focus on optimizing biophysical properties, improving usability, efficacy, and stability of therapeutic proteins.
Conclusion:
Pfenex Inc stands out as a biotechnology leader with a robust range of products and services designed to meet diverse healthcare needs. With a strong commitment to advancing research and development, the company is poised to deliver groundbreaking protein therapies and vaccines, addressing significant challenges in patient care and contributing positively to the healthcare landscape. Through its focus on innovation and collaboration, Pfenex Inc continues to enhance its capabilities to tackle chronic and complex diseases, ultimately improving patient outcomes.